DE102005056393A1 - Pressure-sensitive adhesive, useful particularly for plasters and transdermal drug-delivery systems, contains specific multicyclic hydrocarbon substituted by polar groups - Google Patents

Abstract

Pressure-sensitive adhesive (A) contains at least one multicyclic, saturated or unsaturated hydrocarbon (I) that is substituted by at least one specified functional group. Pressure-sensitive adhesive (A) contains at least one multicyclic, saturated or unsaturated hydrocarbon (I) that is substituted by at least one functional group of formula -(CH2)p-Q. p : 0-6; Q : hydroxy, 1-6C alkoxy, 1-6C alkoxycarbonyl, thiol, cyano, azido, amino (optionally substituted by one or two 1-6C alkyl), 1-6C alkylcarbonylamino, formyl, 1-6C alkylcarbonyl, carboxy, 1-6C alkoxycarbonyl, 1-6C alkylaminocarbonyl or di(1-6C)alkylaminocarbonyl . An independent claim is included for self-adhesive devices for attachment to the skin that include a layer containing (A).

Description

The The invention relates to a pressure-sensitive adhesive which is excellent Has adhesion properties on the skin, so he for example as a medical adhesive for Transdermal Therapeutic Systems and other medical or cosmetic products can be used.

Pressure-sensitive adhesive, for example, those based on polyacrylates, polyisobutylenes, Polysiloxanes or cellulose derivatives are widely used in the manufacture of medical plasters and transdermals Therapeutic Systems (TTS).

With Help from TTS can certain drugs through the skin parenteral, systemic be administered. In doing so, the TTS are able to get the active ingredient transdermal at a certain rate for a set period of time continuously to the organism. In therapy have TTS proves itself, since a painless, convenient and easy administration of an active ingredient to the patient over a longer one Allow period.

• a) eine für den Wirkstoff undurchlässige Trägerschicht,
• b) eine klebefähige Schicht, welche die Trägerschicht zumindest teilweise bedeckt, und
• c) ggf. eine Schutzfolie, welche die klebefähige Schicht zumindest teilweise bedeckt und davon abziehbar ist.

Usually, a TTS includes at least

• a) a carrier layer impermeable to the active substance,
• b) an adhesive layer which at least partially covers the carrier layer, and
• c) optionally a protective film which at least partially covers the adhesive layer and is removable from it.

Regarding The structure and operation of TTS can be between membrane-controlled Systems (reservoir TTS) and matrix-controlled systems (matrix TTS) become.

One Reservoir TTS usually includes a skin self-adhesive, flat pouch containing the Active ingredients dissolved contains. Facing the skin side is the bag with one for the active ingredient permeable membrane equipped, which controls the drug release. Adhesive layer and active ingredient Layer (reservoir) are common spatial separate subunits of a reservoir TTS.

at a matrix TTS, the drug is embedded in a matrix, being in liquid, semi-solid or solid state dispersed or in dissolved form may be present. Does the matrix have adhesive properties at the same time? on, so is the sticky one Layer at the same time also the active substance-containing layer. But it is also possible, that the sticky Layer and the active ingredient-containing layer - as well as a reservoir TTS - from each other are separated. In this case, the adhesive layer can cover area or partially, e.g. annular on the active substance-containing layer or the membrane of the reservoir can be applied.

By the composition and structuring of the matrix and / or the membrane the release of the active substance can be regulated. Regarding For more details, see, for example, T.K. Gosh, transdermal and Topical Drug Delivery Systems It Into Practice, CRC Press, 1997; R. O. Potts et al., Mechanisms of Transdermal Drug Delivery (Drugs and the Pharmaceutical Sciences), Marcel Dekker, 1997; and R. Gunny et al, Dermal and Transdermal Drug Delivery. New Insights and Perspectives, Scientific VG., Stuttgart, 1998 are referenced.

In order to An active substance must be administered with the help of a TTS in sufficient quantity through the epidermis of the skin, in particular also diffuse the stratum corneum, the individual underlying Skin layers pass through and are absorbed by the bloodstream. A major problem is often the only low permeability the skin for certain active ingredients. Depending on the chemical structure and lipophilicity It may therefore be necessary to use the transcutaneous agent Permeation of the active substance from the TTS by addition of suitable auxiliaries to improve.

In addition to the desired pharmacokinetic parameters, a TTS must have sufficient skin tolerance. The adhesion of the TTS to the skin is usually achieved by means of pressure-sensitive adhesives (medical pressure-sensitive adhesive). In order to modify the chemical and / or physical properties, eg the coherence or stickiness of medical pressure-sensitive adhesives and to optimize them depending on the respective requirements, certain auxiliary agents or additives are usually added, in particular plasticizers or tackifiers. However, these auxiliaries or additives should be compatible with the other materials used. Thus, the said auxiliaries or additives should not adversely affect the chemical stability of the active substances contained in TTS or their release. Often it may also be advantageous if the polymer matrix of a pressure-sensitive adhesive containing active predominantly lipophilic properties has a high loading capacity for lipophilic drugs.

Further allowed to the ingredients of such pressure-sensitive adhesive neither allergies nor contact dermatitis and, in particular, should also be repeated if necessary done on the skin and removing the skin gently and no Cause skin irritation.

The Liability of the system on the skin should therefore be sufficient to one to ensure permanent medication But should not be too strong, so a removal after the Application possible without difficulty is. Furthermore, a TTS should be taken frequently for several days by the patient is applied, have sufficient water resistance to it due to the natural Transpiration or showering does not replace by itself. Finally, should a TTS also have sufficient mechanical resistance to it not due to external influences damaged or unintentionally removed.

The The same requirements apply to the adhesive layer other systems, although no drug for transdermal Administration, but on human or animal Skin should be applied. Examples of such applications are conventional patches with a wound dressing, pressure patches, medicated patches for topical treatment, adhesive tapes for fastening bandages, self-adhesive cosmetic products, e.g. for degreasing the skin, and self-adhesive labels for aesthetic Purposes, e.g. for fixing garments or toupees on the skin.

Of the Invention is based on the object, pressure-sensitive adhesives to disposal to provide, which have advantages over the prior art. The pressure-sensitive adhesives should be used as medical Pressure-sensitive adhesives on the skin are suitable, for example for patches or TTS, for sufficient resistance against water and a balance between bond strength on the one hand and removability, on the other hand. The physical and chemical properties, especially stickiness and plastic Characteristics or coherence, should be advantageously modified and improved, all Ingredients compatible with each other and in the case of TTS the stability and release of the transdermal drug to be administered impair should.

These The object is solved by the subject matter of the claims. It became surprising found that certain multicyclic hydrocarbons beneficial can be used in pressure-sensitive adhesives.

One aspect of the invention relates to a pressure-sensitive adhesive containing at least one multicyclic, saturated or unsaturated hydrocarbon which is substituted by at least one functional group, preferably having at least two identical or different functional groups selected from the group consisting of - (CH ₂ ) _p OH , - (CH ₂ ) _p OC _1-6 alkyl, - (CH ₂ ) _p OCO-C _1-6 alkyl, - (CH ₂ ) _p SH, - (CH ₂ ) _p CN, - (CH ₂ ) _{pN 3} , - (CH ₂ ) _p NH ₂ , - (CH ₂ ) _p NHC _1-6 alkyl, - (CH ₂ ) _p N (C _1-6 alkyl) ₂ , - (CH ₂ ) _p NHCO -C _1-6 alkyl, - (CH ₂ ) _p CHO, - (CH ₂ ) _p COC _1-6 alkyl, - (CH ₂ ) _p CO ₂ H, - (CH ₂ ) _p CO ₂ C _{1- 6} alkyl, - (CH ₂ ) _p CONHC _1-6 alkyl and - (CH ₂ ) _p CON (C _1-6 alkyl) ₂ , wherein p is 0, 1, 2, 3, 4, 5 or 6, respectively , preferably 0 or 1, particularly preferably 1. If the multicyclic hydrocarbon is substituted with two or more substituents of the same type, for example with two substituents of the type - (CH ₂ ) _p OH, then p may be different in each case.

The invention relates to a preferably hypoallergenic and hypoallergenic pressure-sensitive adhesive. Pressure-sensitive adhesives are known in principle to the person skilled in the art. In this connection can be made for example to I. Benedek, Pressure-Sensitive Adhesives and Applications, Marcel Dekker, 2 ^nd edition, of 2004.

Of the pressure-sensitive according to the invention Contains adhesive a multicyclic hydrocarbon. "Multicyclic" in this context means that the hydrocarbon of the invention is at least bicyclic. In this case, "bicyclic" preferably means that a correct name of the hydrocarbon according to IUPAC nomenclature (preferably as of 2005) contains the term "bicyclo". The hydrocarbon is preferred tricyclic. Correspondingly, "tricyclo" preferably means that a correct name of the hydrocarbon according to IUPAC nomenclature (preferably as of 2005) contains the term "tricyclo".

In a preferred embodiment, the structure of the multicyclic hydrocarbon derives from a tricyclo [abcd ^{e, f} ] hydrocarbon, where a, b, c, and d are natural numbers and have meaning according to IUPAC nomenclature, and the sum of a , b, c and d are in the range of 6 to 16, more preferably ranging from 8 to 14. The structure of the multicyclic hydrocarbon is preferably derived from this hydrocarbon, ie in addition to the hydrocarbon as a backbone, in addition to the at least one substituent selected from the group consisting of - (CH ₂ ) _p OH, - (CH ₂ ) _P OC _1-6 - Alkyl, - (CH ₂ ) _p OCO-C _1-6 alkyl, - (CH ₂ ) _p SH, - (CH ₂ ) _P CN, - (CH ₂ ) _p N ₃ , - (CH ₂ ) _p NH ₂ , - (CH ₂ ) _p NHC _1-6 alkyl, - (CH ₂ ) _p N (C _1-6 alkyl) ₂ , - (CH ₂ ) _p NHCO-C _1-6 alkyl, - (CH ₂ ) _P CHO, - (CH ₂ ) _p COC _1-6 alkyl, - (CH ₂ ) _p CO ₂ H, - (CH ₂ ) _p CO ₂ C _1-6 alkyl, - (CH ₂ ) _p CONHC _{1 -6-} alkyl and - (CH ₂ ) _p CON (C _1-6 -alkyl) ₂ , where p may be identical or different, 0, 1, 2, 3, 4, 5 or 6, also further substituents may be present, in particular also alkanyl, alkenyl or alkynyl radicals.

• – tricyclo-[a.b.1.0^2,(a+1)]-Kohlenwasserstoff oder
• – tricyclo-[a.b.2.0^2,(a+1)]-Kohlenwasserstoff

ab, wobei a jeweils 5, 6, 7 oder 8 und b jeweils 2, 3 oder 4 ist.In a preferred embodiment, the structure of the multicyclic hydrocarbon is derived from a

• - tricyclo [ab1.0 ^{2, (a + 1)} ] hydrocarbon or
• - tricyclo- [ab2.0 ^{2, (a + 1)} ] hydrocarbon

where a is 5, 6, 7 or 8 and b is 2, 3 or 4, respectively.

Of the multicyclic hydrocarbon is saturated or unsaturated. Unsaturated means in this context, that the hydrocarbon is one or more Carbon-carbon double bonds and / or one or more Carbon-carbon triple bonds contains. If there are several double or triple bonds, these can be conjugated. However, the hydrocarbon is preferably not aromatic and not polymeric. The hydrocarbon is in molecular Form before, i. solid or liquid, dissolved or suspended.

worin
n 1, 2 oder 3 ist;
R₁ und R₂ gleich oder verschieden ausgewählt sind aus der Gruppe bestehend aus -CH₂OH, -CH₂NH₂ und -CHO; und
R³ und R⁴ jeweils -H sind oder zusammen eine -C_1-4-Alkylen-Brücke bilden, wobei die -C_1-4-Alkylen-Brücke ggf. mit einem oder zwei gleichen oder verschiedenen -C_1-6-Alkyl-Resten substituiert sein kann.The hydrocarbon is preferably a compound of the general formula (I)

wherein
n is 1, 2 or 3;
R ₁ and R _{2 are} identically or differently selected from the group consisting of -CH ₂ OH, -CH ₂ NH ₂ and -CHO; and
R ³ and R ^{4 are} each H or together form a C _1-4 alkylene bridge, wherein the C _1-4 alkylene bridge is optionally substituted by one or two identical or different C _1-6 alkyl -Resten may be substituted.

• – tricyclo-[5.2.1.0^2,6]-Kohlenwasserstoff,
• – tricyclo-[6.2.1.0^2,7]-Kohlenwasserstoff,
• – tricyclo-[5.2.2.0^2,6]-Kohlenwasserstoff oder
• – tricyclo-[6.2.2.0^2,7]-Kohlenwasserstoff ab,

wobei ein tricyclo-[5.2.1.0^2,6]-Alkan, insbesondere ein tricyclo-[5.2.1.0^2,6]Decan, besonders bevorzugt ist.More preferably, the structure of the multicyclic hydrocarbon derives from a

• - tricyclo [5.2.1.0 ^2,6 ] hydrocarbon,
• - tricyclo [6.2.1.0 ^2,7] hydrocarbon,
• - tricyclo [5.2.2.0 ^2,6 ] hydrocarbon or
• - tricyclo [6.2.2.0 ^2,7 ] hydrocarbon,

where a tricyclo [5.2.1.0 ^2,6 ] alkane, in particular a tricyclo [5.2.1.0 ^2,6 ] decane, is particularly preferred.

• • bis-(Hydroxymethyl)-tricyclo-[5.2.1.0^2,6]decan ("TCD-Alkohol DM"), – z.B. 3(4),8(9)-bis-(Hydroxymethyl)-tricyclo-[5.2.1.0^2,6]decan, d.h. – 3,8-bis-(Hydroxymethyl)-tricyclo-[5.2.1.0^2,6]decan, – 4,8-bis-(Hydroxymethyl)-tricyclo-[5.2.1.0^2,6]decan, – 3,9-bis-(Hydroxymethyl)-tricyclo-[5.2.1.0^2,6]decan, oder – 4,9-bis-(Hydroxymethyl)-tricyclo-[5.2.1.0^2,6]decan;
• • bis-(Aminomethyl)-tricyclo-[5.2.1.0^2,6]decan, – z.B. 3(4),8(9)-bis-(Aminomethyl)-tricyclo-[5.2.1.0^2,6]decan, d.h. – 3,8-bis-(Aminomethyl)-tricyclo-[5.2.1.0^2,6]decan, – 3,9-bis-(Aminomethyl)-tricyclo-[5.2.1.0^2,6]decan, – 4,8-bis-(Aminomethyl)-tricyclo-[5.2.1.0^2,6]decan, oder – 4,9-bis-(Aminomethyl)-tricyclo-[5.2.1.0^2,6]decan; und
• • bis-Formyl-tricyclo-[5.2.1.0^2,6]decan, – z.B. 3(4),8(9)-bis-Formyl-tricyclo-[5.2.1.0^2,6]decan, d.h. – 3,8-bis-Formyl-tricyclo-[5.2.1.0^2,6]decan, – 3,9-bis-Formyl-tricyclo-[5.2.1.0^2,6]decan, – 4,8-bis-Formyl-tricyclo-[5.2.1.0^2,6]decan oder – 4,9-bis-Formyl-tricyclo-[5.2.1.0^2,6]decan.

Preferably, the hydrocarbon is selected from the group consisting of

• Bis (hydroxymethyl) tricyclo [5.2.1.0 ^2,6 ] decane ("TCD-alcohol DM"), eg 3 (4), 8 (9) -bis (hydroxymethyl) -tricyclo [5.2. 1.0 ^2,6 ] decane, ie - 3,8-bis (hydroxymethyl) tricyclo [5.2.1.0 ^2,6 ] decane, 4,8-bis (hydroxymethyl) tricyclo- [5.2.1.0 ^{2, 6} ] decane, 3,9-bis (hydroxymethyl) tricyclo [5.2.1.0 ^2,6 ] decane, or 4,9-bis (hydroxymethyl) tricyclo [5.2.1.0 ^2,6 ] decane ;
• Bis (aminomethyl) tricyclo [5.2.1.0 ^2,6 ] decane, eg 3 (4), 8 (9) bis (aminomethyl) tricyclo [5.2.1.0 ^2,6 ] decane, ie 3,8-bis (aminomethyl) tricyclo [5.2.1.0 ^2,6 ] decane, 3,9-bis (aminomethyl) tricyclo [5.2.1.0 ^2,6 ] decane, 4,8 bis (aminomethyl) tricyclo [5.2.1.0 ^2,6 ] decane, or 4,9-bis (aminomethyl) tricyclo [5.2.1.0 ^2,6 ] decane; and
• Bis-formyltricyclo [5.2.1.0 ^2,6 ] decane, eg 3 (4), 8 (9) -bis-formyltricyclo [5.2.1.0 ^2,6 ] decane, ie - 3,8 bis-formyl-tricyclo [5.2.1.0 ^2,6 ] decane, 3,9-bis-formyl-tricyclo [5.2.1.0 ^2,6 ] decane, 4,8-bis-formyl-tricyclo [ 5.2.1.0 ^2,6 ] decane or - 4,9-bis-formyl-tricyclo [5.2.1.0 ^2,6 ] decane.

Such tricyclic hydrocarbons can be prepared by conventional methods and sometimes also commercially available. Tricyclo [5.2.1.0 ^2,6 ] decane is obtained, for example, by hydrogenation of the Diels-Alder product of cyclopentadiene.

The present invention opens new and advantageous applications of this and similar Compounds in the medical field, especially in the field of medical pressure-sensitive adhesive products. This is possible because, surprisingly has shown that these multicyclic hydrocarbons highly compatible with the polymers which are commonly used in the manufacture pressure sensitive medical products.

• – ist p = 0 oder 1 und/oder
• – ist der Kohlenwasserstoff tricyclisch, und/oder
• – umfasst der Kohlenwasserstoff 8 bis 30, bevorzugter 9 bis 29, noch bevorzugter 10 bis 28, am bevorzugtesten 11 bis 27 und insbesondere 12 bis 26 Kohlenstoffatome, und/oder
• – ist der Kohlenwasserstoff nicht aromatisch und/oder nicht polymer.

In a preferred embodiment

• - p = 0 or 1 and / or
• The hydrocarbon is tricyclic, and / or
• The hydrocarbon comprises 8 to 30, more preferably 9 to 29, even more preferably 10 to 28, most preferably 11 to 27 and especially 12 to 26 carbon atoms, and / or
• The hydrocarbon is not aromatic and / or not polymeric.

The molecular weight of the multicyclic hydrocarbon is preferably in the range of 120 to 500 g mol ^-1 , more preferably 150 to 300 g mol ^-1 , even more preferably 160 to 250 g mol ^-1 , most preferably 170 to 220 g mol ^-1 and in particular from 180 to 200 g mol ^-1 .

Of the Weight fraction of the multicyclic hydrocarbon, based on the total weight of the pressure-sensitive adhesive is preferred in the range of 0.1 to 50% by weight, more preferably 1.0 to 40% by weight, even more preferably 5.0 to 30% by weight, most preferably 10 to 25 Wt .-% and in particular 12 to 22 wt .-%.

The multicyclic according to the invention Hydrocarbons are highly compatible with the polymers, which usually in pressure-sensitive adhesives (e.g., poly (meth) acrylates or cellulose derivatives).

by virtue of good compatibility formulations are possible which has a comparatively high content of low molecular weight compounds, e.g. Active ingredients, so that in these pressure-sensitive adhesives a facilitated and accelerated Diffusion of active substances is expected. Depending on the substitution pattern The multicyclic hydrocarbons may have the lipophilic character These compounds can be varied so that they are sometimes suitable are, the lipophilicity of the pressure-sensitive adhesive and thus its capacity for lipophilic Increase active ingredients.

Within the pressure-sensitive invention Adhesive, the multicyclic hydrocarbon preferably functions as a tackifier, the pressure-sensitive adhesives of the invention in addition to the multicyclic hydrocarbons further auxiliaries can contain which also act as a tackifier.

In a preferred embodiment, the pressure-sensitive adhesive according to the invention contains, in addition to at least one multicyclic hydrocarbon, an at least partially esterified saccharide, preferably an at least partially esterified disaccharide. Sucrose octaesters, in particular sucrose octaacetate and sucrose-actetate isobutyrate (eg sucrose diacetate hexaisobutyrate), have proved to be particularly suitable. The addition of such esters to pressure-sensitive adhesives leads to plasticization of the polymers and to improved tack, ie the esters act both as plasticizers and as tackifiers. Esters of saccharides are understood to mean those esters in which one, two or more Hydroxyl groups of the saccharide, preferably of the disaccharide, more preferably at least on average half of the hydroxyl groups, most preferably all hydroxyl groups, are esterified. Particularly suitable disaccharides are sucrose and maltose, with esters of sucrose, in particular sucrose octaester, being the most preferred. Fatty acids are primarily understood as meaning saturated acyclic monocarboxylic acids, which may also be branched monocarboxylic acids, for example isobutyric acid. Furthermore, the term "fatty acids" also includes unsaturated fatty acids. According to a particular embodiment, at least a part of the hydroxyl groups of the sugar molecule is esterified with unbranched or branched fatty acids having a chain length of at least 4, preferably from 6 to 12, carbon atoms; the remaining hydroxyl groups are esterified with shorter fatty acids, for example with acetic acid.

Usually can the application properties of a medical adhesive with regard to its Adhesion and skin compatibility can not be determined on the basis of a single measurement. Rather, various test procedures are required, where the properties of the pressure-sensitive adhesive then only from the overall result of all measurements. These tests sometimes count a so-called "peel test", the measurement of Surface tension, adhesion and elasticity, and the determination of the behavior upon contact with water or the Determination of water vapor permeability.

to quantitative determination of the adhesion properties of pressure-sensitive Adhesives are available in various ways, e.g. 180 ° peel, 90 ° peel, drum peel, T peel and lift test. These tests are based on standards from various industry associations manufacturers of pressure-sensitive adhesives (AFERA, PCTC, FINAT, ASTM (e.g., ASTM D903-98)). The individual tests can be pressure sensitive for a given Adhesive, however, lead to quite different results.

At the 90 ° - or 180 ° peel test with the peeling force the force determines which is necessary to make a streak of a stretchable sample from a mostly rigid substrate at an angle of 90 ° or 180 ° peel (see. PSTC. PSTC-1: Peel Adhesion for Single Coated Tapes 180 ° Angle. 12 23-24, Pressure Sensitive Tape Council, 1996, Illinois).

At the 90 ° peel test as a measure of the adhesion properties pressure-sensitive adhesives often the Force required to form a 4 cm wide strip, which over attached the pressure-sensitive adhesive on a flat stainless steel surface is orthogonal at a certain speed (e.g., 50 mm / min) deducted. A preferred according to the invention Method of determination is carried out on a testing machine from Zwick, especially preferably as indicated in Example 4 a). Usually, values become measured that vary within a certain range, so that the average bond strength as the arithmetic mean of the measured Maximum value and the measured minimum value can be specified can.

However, the standardized stainless steel surface to which the pressure sensitive adhesives are applied in this method of determination is limited in their ability to simulate the adhesive properties of a pressure sensitive adhesive on human or animal skin. Thus, on the one hand, for example, the body temperature can play a role and on the other hand, the surface structure of the skin is not completely planar. Furthermore, the skin has pores, hair, lipids, moisture and sometimes also keratin scales. Because of this complex structure, however, it is also difficult to find another standardized surface instead of stainless steel, which, because of its surface structure, is more similar to human or animal skin and ensures reproducible measured values. In the prior art methods for determining the adhesion properties of pressure sensitive adhesives are described in artificial skin (Vitro-Skin ^®, Paraskin ^®). Although the results usually correlate better with the in vivo data, they are also not always completely satisfactory.

Also in the pressure-sensitive invention Adhesive comes the fact that the multicyclic hydrocarbon the adhesion properties improved significantly when determined the adhesion properties according to 90 ° peel test (i.e. with adhesion to a stainless steel surface) only conditionally expressed. More clear will improve the adhesion properties only when one as a test surface the human skin is used, i. selects in vivo conditions. According to the invention preferred the determination of the adhesion properties of the pressure-sensitive Adhesive therefore not with a stainless steel surface as a substrate, preferably also not artificial Skin, but particularly preferably as a perceived adhesive force sensation human or animal skin, for example as in Example 4 b).

However, if the adhesion properties are determined using classical methods, eg 90 ° peel, the determined average bond strength of the system of the invention is preferably in the range of 0.1 to 2.0 N / cm, more preferably in the range of 0.2 to 1.8 N / cm, even more preferably in the range of 0 , 4 to 1.6 N / cm, most preferably in the range of 0.5 to 1.5 N / cm and in particular in the range of 0.6 to 1.4 N / cm.

Next the multicyclic hydrocarbon contains the pressure-sensitive invention Adhesive preferably at least one polymer, preferably selected from the group consisting of polyacrylates, polyvinyl ethers, polyvinyl alcohols, Polyisobutylenes, acrylate copolymers, ethylene-vinyl acetate copolymers, Polyurethanes, styrene-isoprene copolymers, styrene-butadiene copolymers, Cellulose derivatives, silicones, rubbers, resins and optionally hydrogenated Estern of the rosin.

suitable Cellulose derivatives are e.g. Ethylcellulose, propylcellulose, hydroxyethylcellulose, Hydroxypropylcellulose and hydroxypropylmethylcellulose.

suitable Polyacrylates are e.g. (Co) polymers of acrylates, alkyl acrylates, Methacrylates, and / or alkyl methacrylates, optionally with other unsaturated Monomers such as acrylamide, dimethylacrylamide, dimethylaminoethyl acrylate, Hydroxyethyl acrylate, hydroxypropyl acrylate, methoxyethyl acrylate, Methoxyethyl methacrylate, acrylonitrile and / or vinyl acetate copolymerized are.

in the As used herein, "(meth) acrylic" means "acrylic" and / or "methacrylic".

Particularly suitable (meth) acrylic esters are those which carry linear, branched or cyclic aliphatic C ₁ -C ₂ -substituents without other functional groups. In particular, this group includes methyl (meth) acrylate, ethyl (meth) acrylate, isopropyl (meth) acrylate, n-butyl (meth) acrylate, isobutyl (meth) acrylate, sec-butyl (meth) acrylate, tert-butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, cyclohexyl (meth) acrylate and isobornyl (meth) acrylate.

But can also (meth) acrylic acid esters in the monomer mixture used to prepare the polyacrylate be included, carry the functional groups. Below are et al to understand hydroxyl-containing esters, such as 2-hydroxyethyl (meth) acrylate and 3-hydroxypropyl (meth) acrylate. But also substances like acrylamide, Dimethylaminoethyl acrylate etc. can understood as containing functional groups (meth) acrylic acid esters become. The proportion of (meth) acrylic acid esters containing such functional Contain groups should be smaller or equal in the monomer mixture 10% by weight, preferably less than 2% by weight, more preferably less as 0.2 wt .-%, amount. Particularly preferred is a monomer mixture, the non-functional group-containing (meth) acrylic acid ester contains.

However, it is also possible to use vinyl acetate as co-monomer together with at least one monomer from the group of the (meth) acrylic esters for the preparation of the polyacrylate. The proportion of vinyl acetate in the monomer mixture used to prepare this polyacrylate should be below 50% by weight, preferably below 25% by weight. Particularly preferred is a vinyl acetate content between 0 and 5.0 wt .-%. Especially preferred acrylate-vinyl acetate copolymers, which are available, for example under the name DUROTAK ^® are commercially available. These copolymers are particularly preferably used in combination with polyacrylates, such as Carbopol ^®, especially Carbopol ^® 980, or hydroxypropyl cellulose.

According to the invention the weight ratio of the multicyclic hydrocarbon to that listed above, at least a polymer preferably in the range of 10: 1 to 1: 100, more preferably 5: 1 to 1:50, more preferably 1: 1 to 1:10 and most preferably 1: 1 to 1: 5.

Of the pressure-sensitive according to the invention Adhesive may contain other adjuvants that apply it on the human skin. Examples for such Auxiliary substances are skin permeation-promoting substances, solvents, Solubilizers, Emulsifiers, crosslinkers, stabilizers, preservatives, dyes, skin-smoothing Medications, perfumes, for reducing or preventing skin irritation transferable to the skin surface Compounds, thickeners, plasticizers, tackifiers, etc. Such adjuvants are known to the person skilled in the art. In this context For example, reference may be made to H.P. Fiedler, Lexicon of Excipients for Pharmacy, cosmetics and related areas, Editio Cantor Aulendorff, 2002; R. Niedner et al., Dermatics: Therapeutic Use, Pharmacology and pharmacy, Wiss. Verl.-Ges. 1992. Concrete examples of the above The substance classes mentioned below are also related described with further aspects of the invention.

One Another aspect of the invention relates to a self-adhesive device for attachment to the skin comprising an adhesive layer, which contains a pressure-sensitive adhesive described above.

• – ein Transdermales Therapeutisches System,
• – ein wirkstoffhaltiges Pflaster, wobei der Wirkstoff im wesentlichen nur topisch, nicht jedoch transdermal/systemisch verabreicht wird,
• – ein Pflaster, welches keinen pharmazeutischen Wirkstoff enthält (z.B. ein herkömmliches Pflaster mit einer Wundauflage oder ein Druckstellenpflaster), oder
• – ein sonstiger selbstklebender Gegenstand, welcher dazu bestimmt ist, auf der Haut aufgebracht zu werden (z.B. ein Klebeband zur Befestigung von Verbänden, ein selbstklebendes kosmetisches Produkt, etwa zur Entfettung der Haut, und ein selbstklebendes Etikett für ästhetische Zwecke, etwa zur Fixierung von Kleidungsstücken oder Toupets auf der Haut),

umfassend eine klebefähige Schicht basierend auf einem vorstehend beschriebenen, erfindungsgemäßen, druckempfindlichen Klebstoff.Preferably, the self-adhesive device

• A Transdermal Therapeutic System,
• A medicated plaster wherein the active ingredient is administered substantially only topically, but not transdermally / systemically,
• A plaster which does not contain a pharmaceutical active substance (eg a conventional patch with a wound dressing or a pressure patches), or
• - Another self-adhesive article, which is intended to be applied to the skin (eg an adhesive tape for attaching dressings, a self-adhesive cosmetic product, such as for degreasing the skin, and a self-adhesive label for aesthetic purposes, such as the fixation of garments or toupees on the skin),

comprising a tacky layer based on a pressure-sensitive adhesive of the invention described above.

In a particularly preferred embodiment it is a medicated plaster or a TTS, which is e.g. configured as a matrix TTS or as a reservoir TTS can be.

The TTS according to the invention comprises preferably at least one for the active ingredient impermeable carrier layer, a sticky one Layer, which is the carrier layer at least partially covered, and optionally a protective film which the capable of adhesion Layer is at least partially covered and removable from it. Of the Active ingredient can be in the adhesive Layer (drug in adhesive) and / or another layer, for example in one of the sticky Layer separated matrix (drug in matrix), be contained.

In a preferred embodiment the transdermally administered drug is at least partially in the sticky Layer included. In a preferred embodiment, the transdermal at least partially in a matrix embedded, wherein the matrix in turn part of the adhesive layer be or an independent one Layer can form.

In a preferred embodiment is the TTS according to the invention is a matrix TTS. The matrix TTS preferably comprises a carrier layer, from which a surface to the Matrix adjoins which the transdermally administered drug contains (active substance-containing layer), and a sticky layer. The adhesive layer preferably covers the entire surface of the carrier layer. The in between lying matrix preferably covers only a part of the surface of Support layer, leaving an outer edge the carrier layer which remains with the adhesive layer, but not covered with the matrix. To the migration of the drug into the backing To minimize, it may be advantageous between backing layer and matrix to insert a barrier layer of a suitable material. The capable of adhesion Layer is preferably provided with a removable protective film.

at the matrix TTS according to the invention is the transdermal drug to be administered at least in part embedded in a matrix (active substance-containing layer). The matrix is preferably based on lipophilic or hydrophilic, preferably crosslinkable polymers. Hydrophilic matrix-forming layers can contain water which are preferably gels in such a case. Preferably, the matrix is based on at least one polymer selected from the group comprising cellulose derivatives, e.g. Cellulose ethers, particularly preferably methylcellulose, ethylcellulose, propylcellulose, Hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and / or carboxymethylcellulose; Polyethylene; chlorinated polyethylenes, such as polyvinyl chlorides or polyvinylidene chlorides; Polypropylene; polyurethanes; polycarbonates; polyacrylate; polyacrylates; polymethacrylates; polyvinyl alcohols; polyvinylpyrrolidones; Polyethylene terephthalate; polytetrafluoroethylene; Ethylene-propylene copolymers; Ethylene-ethyl acrylate copolymers; Ethylene-vinyl acetate copolymers; Ethylene-vinyl alcohol copolymers; Ethylene-vinyloxyethanol copolymers; Vinyl chloride-vinyl acetate copolymers; Vinylpyrrolidone-ethylene-vinyl acetate copolymers; rubbers; synthetic homo-, co- or block polymers of butadiene and / or styrene, such as styrene-isoprene-styrene block copolymers; silicones; Silkon derivatives, more preferably siloxane-methacrylate copolymers, Polyvinyl ethers, polyesters, and / or polysaccharides, or mixtures thereof. Particular preference is given to polyacrylates or acrylate copolymers, in particular those as described above in connection with Polymers of the pressure-sensitive invention Adhesive are described.

In a further preferred embodiment If the TTS according to the invention is a so-called "monolithic drug-in-adhesive TTS "in this Case is the drug to be transdermally administered in the adhesive layer contain (drug in adhesive). Such a TTS preferably comprises a carrier layer, a sticky one Layer containing the active ingredient, and optionally a removable protective film. The active substance-containing layer may additionally comprise matrix-forming polymers so that the active ingredient is embedded in a matrix (drug in matrix), which in turn is part of the adhesive layer of the TTS is (drug in adhesive). For producing such an adhesive layer can the components of the pressure-sensitive adhesive of the invention as sticky Component with the matrix materials listed above be mixed known amounts and for the preparation of the active ingredient Matrix area to be added to a physiologically active substance. After application, the matrix material can also be crosslinked if necessary. The drug present in the matrix or present in the matrix Active ingredients can liquid, semi-solid or solid in the dispersed state or as appropriate Formulation with addition from usual Excipients may be incorporated as an active ingredient formulation.

Provided the TTS invention no all-over capable of adhesion Layer, it may also be designed so that the pressure-sensitive Adhesive is present only in the edge zones of the active substance-containing layer, these edge zones preferably contain no active ingredient.

In a further preferred embodiment TTS is a multi-layered system where the transdermal at least partially in the adhesive layer is included. In this embodiment at least one selectively permeable membrane is present between two adhesive layers, both being adhesive Layers are active ingredient-containing (see T. A. Petersen et al., Intern. Symp. Control. Rel. Bioact. Mater., 21: 477-478). Suitable selectively permeable membranes are commercially available (See, e.g., R. E. Kesting, Synthetic Polymer Membranes, McGraw Hill; J.D. Ferry, Ultrafiltration Membranes, Chemical Review, 18, 373).

In another preferred embodiment If the TTS according to the invention is a reservoir TTS. The reservoir TTS according to the invention preferably comprises a carrier layer and a reservoir containing the drug to be transdermally administered in dissolved or suspended form, wherein the reservoir at least on the side, which in the application facing the skin, surrounded by a selectively permeable membrane is. The carrier layer preferably has a certain mechanical resistance and possibly side walls. The capacity of the reservoir is of the spatial Extension of the cavity thus formed dependent. The adhesive layer can over the entire area of the reservoir TTS, which faces the skin during application is, extend. But it is also possible that only parts of this area with the sticky Layer are covered, such as only the skin-facing surface of the carrier layer, which are not with the reservoir or the selectively permeable membrane is covered.

These it is a reservoir TTS, so is the transdermally administered Active ingredient in a reservoir in front. The reservoir is preferably enclosed by a selectively permeable membrane or at least bounded on one side by this. As membrane materials are those listed above Suitable polymers, which are also used as matrix material can. Preferably, the membrane is based on at least one polymer selected from the group consisting of polyethylenes, polypropylenes, polyvinyl acetates, Polyamides, ethylene-vinyl acetate copolymers, polyethylene terephthalates and silicones. With the help of the reservoir membrane can be removed from the reservoir a controlled release of the active ingredient can be achieved.

The The reservoir may preferably be between a cover layer and the adhesive layer be arranged. The reservoir may also be referred to as a non-woven fabric or the like formed with the active ingredient formulation soaked is.

The Reservoir contains at least one active substance to be administered transdermally, preferably as a solution, which diffuse freely through the membrane enclosing the reservoir can. The solution can be an increased viscosity For example, it may be a hydrogel or to act a lipogel. A hydrogel contains primarily hydrophilic substances, but not necessarily water. As solvents are such solvents suitable in which the active ingredient dissolves sufficiently, so that thereby a precipitate the active ingredients is avoided.

As customary adjuvants of TTS, compounds which enhance or facilitate the transdermal transport of the active ingredients (skin permeation-promoting substances) can be used. It may promote the skin permeation known to those skilled in the art for the particular agent to be administered transdermally the substances are used. For example, reference may be made to DS Hsieh, Drug Permeation Enhancement: Theory and Applications (Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs), Marcel Dekker, 1994, and EW Smith et al., Percutaneous Penetration Enhancers, CRC Press , 1995.

Examples of skin permeation promoting substances are selected from the group consisting of surfactants {eg nonionic surfactants, amphoteric surfactants, anionic surfactants, cationic surfactants, etc, including fatty acid esters, fatty alcohols, polyoxyethylene hardened castor oil (HCO), such as HCO-10, HCO-40, HCO-50, HCO-60; Polysolvate (Tween ^®), such as Tween ^® -60, Tween ^® -65, Tween ^® -80; Sorbitan esters such as sorbitan trioleate, sorbitan monopalmitate, sorbitan monolaurate, sorbitan sesquioleate, polyoxyethylene / polyoxypropylene sorbitan mono-fatty acid esters, sorbitan-polyoxyethylene (160) -polyoxypropylene (30) glycol monostearate; Glycerol esters such as glycerol monostearate, triacetin; benzalkonium chloride; Benzetonium chloride}; Amines {eg monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine}; inorganic bases {eg NaOH, KOH, Ca (OH) ₂ , NaHCO ₃ }; polyvinylpyrrolidone; long-chain alcohols {such as dodecanol, undecanol, octanol}; Propylene glycol; benzyl alcohol; Menthol; isosorbide; Dodecylazacycloheptan-2-one; Lactic acid; ethanol; Esters of carboxylic acids with polyethoxylated alcohols, diesters of aliphatic dicarboxylic acids such as adipic acid, and medium chain triglycerides of caprylic and / or capric acid, coconut oil, polyhydric alcohols such as 1,2-propanediol, esters of polyhydric alcohols such as glycerol with levulinic acid or caprylic acid, and etherified polyhydric alcohols.

Further can the active substance-containing layer (adhesive layer, matrix or reservoir) at least one solvent contained, e.g. Water and / or optionally short chain alcohols, e.g. Ethanol, n-propanol, isopropanol, propylene glycol, glycerol or 1,3-butanediol; Esters, e.g. Isopropyl myristate, ethyl oleate, lauryl lactate, glycerol monooleate, Propylene glycol monocaprylate, sorbitan monooleate or sorbitan trioleate; Transcutol; solketal; Oleic acid; 1-methyl-pyrrolidone; triacetin; or surfactant compounds or mixtures thereof.

Further may be the active substance-containing layer - possibly next to matrix-forming Polymers and / or skin permeation-improving substances - conventional excipients included, e.g. Solvent, Solubilizers, emulsifiers, Crosslinkers, stabilizers, preservatives, plasticizers, dyes, skin-smoothing Agents, perfumes and / or thickeners. To produce pH-controlled Conditions on the skin can as adjuvants e.g. weak acids, weak bases or (on) organic salts which are a buffer system on the skin, be added. Furthermore, the addition of Crystallization inhibitors or fumed silica in a penetration-promoting Quantity possible.

All Materials used to construct transdermal systems but especially those materials that are with the skin in touch should come, should be tolerated by the skin and physiologically harmless.

When Stabilizers, emulsifiers and thickeners are the the Expert known excipients used.

When Stabilizers can Antioxidants, such as vitamin E, butylhydroxytoluene, butylhydroxyanisole, Parabens, ascorbic acid, Ascorbyl palmitate, and / or chelating agents, such as disodium ethylenediaminetetraacetic acid, potassium or sodium citrate. Suitable preservatives also PHB esters, such as PHB methyl esters and PHB propyl esters, benzalkonium chloride, chlorhexidine, sorbic acid, benzoic acid, propionic acid, salicylic acid and their salts, formaldehyde and paraformaldehyde, hexachlorophene, o-phenylphenol, Zinc pyrithione, inorganic sulfites, sodium iodate, chlorobutyl, dehydroacetic acid, formic acid, dibromohexamide, Merthiolate, phenylmercuric salts (phenyl-Hg compounds), undecylenic acid, hexetidines, Bronidox, bronopol, 2,4-dichlorobenzyl alcohol, triclocarban, parachlorometacresol, Triclosan, parachlorometaxylenol, imidazolydinyl-urea derivatives, polyhexamethylene biguanidochlorohydrate, Phenoxyethanol, methenamine, dowicil 200, 1-imidazolyl- (4-chlorophenoxy) -3,3'-dimethylbutan-2-one, Dimethylhydantoin, benzyl alcohol, 1-hydroxy-4-methyl-6- (2,4,4-trimethyl-pentyl) -2-pyridone, 1,2-dibromo-2,4-dicyanobutane, 3,3'-dibromo-5,5'-dichloro-2,2-dihydroxydiphenylmethane, Isopropyl metacresol, Kathon, bisulfite etc.

Preferred thickeners are gelatin, Vaseline, Olesäureoleylester (eg Cetiol ^® ), Komplexemulgatorgele (eg Lanettewachs ASS, Lanette ^® N), semi-synthetic fats (eg Softisan), fumed silica (eg Aerosil ^® ) and / or Bentonit (eg Veegum ^® , Volclay ^© , Ben-A-Gel). As a gelling agent and also thickeners can methylcellulose (eg Methocel ^®, Tylose ^® MW, Tylose ^® MB), hydroxypropyl cellulose (eg Klucel ^®), hydroxyethyl cellulose (eg Ethoxose ^®), hydroxypropyl methylcellulose (eg Methocel ^® E, Methocel ^® K), polyacrylic acid ( for example Carbopol ^®), carboxyvinyl polymer, carbomer copolymer, Na trium polyoxilate, carboxymethyl cellulose or a mixture of at least two of said compounds.

When solubilizers or emulsifiers can N-methyl-2-pyrrolidone, laurylpyrrolidone, Triethanolamine, triacetin, diethylene glycol monoethyl ether, derivatives of fatty acids or fatty alcohols, low molecular weight, polyhydric alcohols such as Propylene glycol or glycerol and / or surfactant compounds used become.

When Plasticizers can e.g. Phthalates such as dibutyl phthalates, mineral oils, esters of citric acid or Esters of glycerin are used.

In a preferred embodiment contains the TTS according to the invention at least a perfume. Particularly preferably, the system contains as a fragrance at least one natural one or nature-identical compound selected from the group comprising Anethole, benzaldehyde, benzyl acetate, benzyl alcohol, benzyl formate, iso-bornyl acetate, camphene, neral, citronellal, citronellol, citronellyl acetate, para-cymene, decanal, dihydrolinalool, dihydromyrcenol, dimethylphenylcarbinol, Eucalyptol, geraniol, geranyl acetate, geranyl nitrile, cis-3-hexenyl acetate, Hydroxycitronellal, limonene, linalool, linalooloxide, linalyl acetate, Linalylpropionate, methylanthranilate, alpha-methylionone, methylnonylacetaldehyde, Methylphenylcarbinyl acetate, menthone, iso-menthone, myrcene, myrcenyl acetate, Myrcenol, nerol, neryl acetate, nonyl acetate, phenylethyl alcohol, alpha-pinene, beta-pinene, gamma-terpinene, alpha-terpinol, beta-terpinol, terpinyl acetate, para-tert-butylcyclohexyl acetate, alpha-amylcinnamaldehyde, Amylsalicylate, caryophyllene, cedrene, cinnamyl alcohol, dimethylbenzylcarbinylacetate, ethylvanillin, Eugenol, iso-eugenol, tricyclodecenyl acetate, piperonal, 3-cis-hexenyl salicylate, Hexyl salicylate, lilial, gamma-methyl ionone, nerolidol, patchouli alcohol, Phenylhexanol, beta-selenines, trichloromethylphenylcarbinylacetate, Triethyl citrate, vanillin, dimethoxybenzaldehyde, benzophenone, ethylene brassylate, Galaxolide, hexylcinnamaldehyde, lyral, methylcedrylon, methyl-beta-naphthylketone, Musk ketone, phenylethyl phenylacetate, ambrettolide, cyclohexyl salicylate, delta-nonalactone, delta-undecalactone, dodecalactone, ethyl undecylenate, exaltolide, gamma undecalactone, hexadecanolide, Myristicin and musk xylene. Other fragrances comprising the TTS according to the invention can, are in David J. Rowe, Chemistry and Technology of Flavors and Fragrances, Taylor & Francis Group, 2004; Michael Edwards, Fragrances of the World 2005, Crescent House Pub, 2004 and David Pybus, The Chemistry of Fragrances, Royal Society of Chemistry, 1999.

Preferably the fragrances are volatile. They are preferred as oils used. As a fragrance, at least one naturally occurring Blend of fragrances can be used. In particular, is suitable comprising at least one fragrance mixture selected from the group Rosemary oil, sandalwood oil, violet oil, lemongrass oil, lavender blossom oil, eucalyptus oil, peppermint oil, chamomile oil, clove leaf oil, cinnamon oil, thyme oil, tea tree oil, cajeput oil, niaouli oil, manuka oil, citrus oil, mountain pine oil, jasmine oil, geranium oil, caraway oil, pine oil, bergamot oil, turpentine oil, linalol oil, blood orange oil, Cypress oil, fir-tree oil, fennel oil, grapefruit oil, ginger oil, pine oil, lavandin oil, lemongrass oil, lime oil, tangerine oil, lemon balm oil, myrrh oil, patchouli oil, rosewood oil and thuja oil.

In a preferred embodiment the fragrance is initially partially in microcapsules and / or cyclodextrins included before. Advantageously, these give microcapsules or cyclodextrins on opening the packaging and / or by the force during application of the TTS on the skin, preferably by the slight contact pressure the patient, the perfume immediately when using the TTS free.

In a preferred embodiment contains the TTS invention a on the skin surface transmissible to reduce or prevent skin irritation Connection. The on the skin surface for reduction or prevention of skin irritability transmissible Compound is preferably a skin-friendly compound selected from the group comprising paraffins, camphor, silanols, silicones, silicone derivatives, Mono-, di- or polyalcohols, natural or artificial Lipids, ceramides, natural or artificial Waxes, natural or artificial Fat, saturated or unsaturated fatty acids and / or fatty alcohols, natural or artificial oils (e.g. Evening primrose oil, Borage oil, Currant seed oil, Fish oils, Cod liver oil), natural or artificial Polymers, starches, Proteins, vitamins, compounds with anti-inflammatory or anti-inflammatory Properties, compounds for preventing the growth of inflammatory Microorganisms, compounds with anesthetic properties, Compounds effective as radical scavengers, enzymes, plant extracts, Preservatives and their mixtures of at least two compounds a class or at least two different classes of Links.

Especially Preferably, at least one skin-compatible compound is selected from the group comprising polymers, preferably fluorinated polyethers, particularly preferably polyperfluoromethyl isopropyl ether, or silicone derivatives, Compounds with anti-inflammatory or anti-inflammatory properties, preferably cortidoids or Antihistaminica, compounds for preventing the growth of pro-inflammatory Microorganisms, preferably antiseptics or antiinfectives, and Compounds effective as radical scavengers, preferably N-acylethanolamine.

When Silicone derivatives are preferably optionally substituted Polysiloxanes optionally mixed with acrylate polymers.

When Compounds with anti-inflammatory or antiphlogistic properties are preferably allantoin, Dexpanthenol, bisabolol, chamazulene, aescin, bas. Aluminum acetate-tartrate, Zinc oxide, tannins, melatonin, Peru balsam, bismuth gallate, their Derivatives and / or salts. As corticoids are preferably Hydrocortisone, betamethasone, fluocinolone acetonide, fluocinonide, prednisolone, Methylprednisolone, triamcinolone, flumetasone, clobetasol, flupredniden, Alclometasone, prednicarbate, mometasone, fluticasone, halcinonide, clocortolone, Diflucortolone, desoximetasone and / or their derivatives. Suitable as antihistamines preferably diphenhydramine, dimetinden, isoprenaline, clemastine, Bamipin, its derivatives and / or salts.

When Compounds for preventing the growth of inflammatory Microorganisms are preferably benzalkonium chloride such as e.g. Benzethonium chloride, methyl hydroxybenzoate, propyl hydroxybenzoate, Chlorhexidine, dequalinium chloride, clioquinol, sorbic acid, whose Derivatives and / or salts.

When Antiseptics are preferably povidone-iodine, iodoform, thymol, Tyrothricin, chlorocresol, salicylic acid, ethacridine or polidocanol, their derivatives and / or salts.

When Anti-infective agents are preferably framycetin, neomycin, gentamicin, Nystatin, erythromycin, tetracycline, chlortetracycline, oxytetracycline, Fusidic acid, metronidazole, Bacitracin zinc, miconazole, amphotericin B, their derivatives and / or Salts.

When Compounds with anesthetizing properties are preferably suitable Benzocaine, lidocaine, tetracaine, prilocaine, mepivacaine, their derivatives and / or salts.

When Vitamins are preferably fat-soluble vitamins, vitamin A. Derivatives, preferably retinol acetate or palmitate, vitamin B Derivatives, vitamin C derivatives, e.g. the corresponding palmitate, Vitamin D derivatives, preferably colecaliciferon or vitamin E. Derivatives, preferably α-tocopherol acetate.

When Enzymes are preferably superoxide dismutase or catalase.

When Plant extracts are preferably extracts from plants such as. Aloe vera, arnica, basil, blackthorn (Lat .: Prunus spinosa), size Burdock (Lat .: Arctium lappa), Marigold (Lat .: Calendula officinalis), Camellia (Lat .: Camellia oleifera), Clary Sage (Lat .: Salvia clarea), chamomile (Lat .: Matricaria chamomilla), comfrey (lat .: Symphytum officinale), coneflower (Lat .: Echinacea angustifolia), Cucumber (lat .: Cucumis sativus), eyebright (lat .: Euphrasia officinalis), Ginseng, greener Tea, lavender, chamomile (Lat .: Chamomilla recutita and Matricaria chamomilla), peppermint (Latin: Mentha piperita), mugwort, nutmeg, Oats (Lat .: Avena sativa), Sandelbaum, Florsafran (Lat .: Carthamus tinctorius), soy, tea tree (lat .: Melaleuca alternifolia), vetivergrass (Lat .: Vetiveria zizanioides), Violet, Licorice (Lat .: Glycyrrhiza glabra) and / or witch hazel (Lat .: Hamamelis).

From the compounds mentioned are preferably those compounds, which is also a skin smoothing Have property. So are also suitable as skin irritation at least reducing compound at least one skin-smoothing compound from the group comprising glycerol, chitosan, hydroxypropylmethylcellulose, cetearyl Octanoate, vitamin E, coconut oil, peanut oil, soybean oil and Butyrospermum Parkii (Shea Butter).

The transferable to the skin surface, Skin irritation at least reducing, skin-friendly compound is preferably as a component in the adhesive layer and / or on the adhesive Layer of the TTS according to the invention.

If this compound in the adhesive Layer is present, it may be dissolved and / or dispersed therein. If the sticky Layer is also a drug-containing layer at the same time, can solved this connection and / or dispersed together with the active ingredient in the adhesive according to the invention available. According to the arrangement of the adhesive layer in the TTS according to the invention is also preferably the arrangement of reducing the skin irritation Connection.

If the transferable to the skin surface, Skin irritation at least reducing compound attached to the nonadhesive Layer is adjacent, it lies between the adhesive layer and the protective film, wherein when peeling off the protective film, the compound on the sticky Layer remains. Preferably, the arrangement of the skin compatible Connection on the adhesive Layer according to the arrangement of the adhesive layer in the plaster according to the invention.

If the transferable to the skin surface, Skin irritation at least reducing, skin-friendly compound at the sticky Layer adjacent, it may according to the arrangement the sticky one Layer evenly distributed, preferably nationwide in the form of a film or a layer, or selectively, for example in multiparticulate Shape, spread over the surface the adhesive layer be upset.

If the transferable to the skin surface, Skin irritation at least reducing, skin-friendly compound in multiparticulate Is present, it may preferably be in micro- or nano-capsules, Micro- or nano-particles or liposomes are present.

The transferable to the skin surface, Skin irritation at least reducing compound is preferred a component of the adhesive Layer, which compound may only in a subsector of nonadhesive Layer may be present. This subsector can also act as a reservoir for the skin-friendly compound be designed. Alternatively, the transferable to the skin surface, Skin irritation at least reducing compound preferably also as a layer preferably having a thickness <5 μm, particularly preferred from 0.5 to 2 μm lie between the removable protective film and the adhesive layer.

For the expert it goes without saying that is transferable to the skin surface, Skin irritation at least reducing compound, be this compound in or on the stickable Layer, only in such an amount that the adhesive effect the sticky one Do not shift or at most only slightly impaired becomes.

The TTS according to the invention can more usual Auxiliaries and additives. These excipients can be used with the active ingredients mixed or in a separate layer to the drug-containing Layer present.

The Layer thickness of the adhesive Layer of the TTS is preferably 3 to 100 μm, preferably 5 to 90 microns and in particular 10 to 80 microns.

The TTS invention draws characterized by a good wearing comfort. Skin irritation during the Wear is avoided and ensure the mechanical properties a sufficient resistance against external influences. comfort and durability against mechanical external influences coordinated.

The TTS according to the invention, preferably the pressure-sensitive invention Adhesive, i. the sticky Layer of TTS, one or more transdermally administrable, contain physiologically active substances, such as pharmaceutical Active substances (medicines), but also food or dietary supplements. The physiologically active substance may be systemic or topical be effective. Preferably contains the TTS according to the invention at least a transdermally administrable substance which is systemically effective is. In the TTS invention can be the physiologically active substance in different physical states as molecularly distributed, as crystals, in the form of clusters or encapsulated in liposomes.

Examples for transdermal administrable food or dietary supplements are proteins, saccharides, Lipids, vitamins, provitamins, trace elements, saturated or unsaturated fatty acids and antioxidants.

The TTS according to the invention preferably contains one or more active substances, but preferably only a single transdermally administered active ingredient. The active ingredient is preferably at least embedded in part in a matrix, wherein the matrix is preferably at least partially formed by the pressure-sensitive adhesive according to the invention.

When Active substances are basically suitable all transdermally administered drugs. Preferably, the Active ingredient selected from the group consisting of antiallergic drugs; antiarthritic; antiasthmatics; Antibiotics and other antimicrobials such as tetracyclines, Oxytetracycline, chlortetracycline, sulfonamide; antidepressants; Antidiabetics, such as insulin; antiepileptic drugs; antihistamines; antihypertensives; Anti-convulsants, such as atropine, butylscopolamine bromide; Anti-migraine agents; antipyretics; anti-inflammatory drugs; antiviral agents; anxiolytics; cardiaca; cardiovascular Compounds such as nitroglycerin, cardiac glycosides; coronary dilators; corticosteroids; anti-inflammatory resources; enzymes; fungicides; Immunomodulators; vaccines; contraceptives; local anesthetics; Means for the treatment of alcohol and / or drug and / or drug dependence; Agents for the treatment of diseases of the central nervous system; Agents for the treatment of neurodegenerative diseases, in particular for the treatment of Parkinson's disease and / or Alzheimer's disease; narcotics and analgesics such as benzocaine, lidocaine, prilocaine; non-steroidal anti-inflammatory drugs or anti-inflammatory Compounds such as indomethacin, diclofenac; nicotine; Opioids (including opiates); Psychotropic drugs such as 3- (2-aminopropyl) indole acetate and 3- (2-aminobutyl) indole acetate; sedative such as sodium pentobarbiturate, phenobarbiturate, secobarbiturate sodium, Codeine, carbromat; (Sexual) hormones, such as adrenocorticosteroids, such as 6-α-methylprednisolone, androgenic steroids, such as methyltestosteroids, fluoxymesterone, estrogens Steroids, like estrogen, 17-β-estradiol, Ethinylestradiol, progesterone, norethindrone, thyroxine; stimulants; Tranquillizers, such as reserpine, chlorpromazine hydrochloride; and vitamins.

In a preferred embodiment the active ingredient is selected from the group consisting of narcotics, opioids (including opiates), Tranquillizers, preferably benzodiazepines, stimulants and others Narcotics.

In a preferred embodiment it is the active ingredient is an analgesic. Prefers are used according to the invention as an analgesic those pharmaceutical agents understood by the WHO assigned to the ATC index N02 (preferably in the official German version of 1 January 2005). Preferred analgesics are "opioids" (ATC code N02A), "other analgesics and antipyretics "(ATC Code N02B) and "migraine agents" (ATC code N02C). Within the more preferred opioids, the "natural" ones are particularly preferred Opium alkaloids "(ATC code N02AA), "phenylpiperidine derivatives" (ATC code N02AB), "diphenylpropylamine derivatives" (ATC code N02AC), "benzomorphan derivatives" (ATC code N02AD), "oripavine derivatives" (ATC code N02AE) , "Morphinan derivatives" (ATC code N02AF), "Opioids in combination with Spasmolytics "(ATC code N02AG) and" other opioids "(ATC code N02AX).

In a particularly preferred embodiment the active ingredient is an opioid. As opioids are particularly suitable preferably μ-, κ- or δ-opioid receptor agonists, most preferably μ-opioid receptor agonists.

In a preferred embodiment, the active ingredient is a transdermally administrable opioid, tranquilizer or other anesthetic selected from the group consisting of alfentanil, allobarbital, allylprodin, alphaprodine, alprazolam, amfepramone, amfetamine, amfetaminil, amobarbital, anileridine, apocodin, barbital, Benzylmorphine, bezitramide, bromazepam, breadizolam, buprenorphine, butobarbital, butorphanol, camazepam, cathine (D-norpseudoephedrine), chlordiazepoxide, clobazam, clonazepam, clonitazen, clorazepate, clotiazepam, cloxazolam, cocaine, codeine, cyclobarbital, cyclorphan, cyprenorphine, delorazepam, desomorphine , Dextromoramide, dextropropoxyphene, dextromethorphan, decocin, diampromide, diamorphone, diazepam, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, dronabinol, eptazocine, estazolam, ethoheptazine, ethylmethylthiambutene, ethylloflazepate, ethylmorphine, etonitazene, etorphine, fencamfamine, fenetylline , Fe nproporex, fentanyl, fludiazepam, flunitrazepam, flurazepam, halazepam, haloxazolam, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, hydroxymethylmorphinan, ketazolam, ketobemidone, levacetylmethadol (LAAM)), levomethadone, levorphanol, levophenacylmorphan, levoxemacin, lofentanil, loprazolam, lorazepam, Lormetazepam, mazindol, medazepam, mefenorex, meperidine, meprobamate, meptazinol, metazocine, methylmorphine, metamfetamine, methadone, methaqualone, methylphenidate, methylphenobarbital, methyprylon, metopon, midazolam, modafinil, morphine, myrophin, nabilone, nalbuphen, nalorphine, narcein, nicomorphine. Nimetazepam, nitrazepam, nordazepam, norlevorphanol, normethadone, normorphine, norpipanone, opium, oxazepam, oxazolam, oxycodone, oxymorphone, papaver somniferum, papaveretum, pernoline, pentazocine, pentobarbital, pethidine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, pholcodeine, phenmetrazine , Phenobarbital, Phentermine, Pinazepam, Pipradrol, Piritramide, Prazepam, Prem ethadione, profadol, proheptazine, Promedol, propranidine, propoxyphene, remifentanil, secbutabarbital, secobarbital, sufentanil, temazepam, tetrazepam, tilidine (cis and trans), tramadol, triazolam, vinylbital, (1R *, 2R *) - 3- (3-dimethylamino-1-ethyl) 2-methyl-propyl) -phenol, (1R, 2R, 4S) -2- [dimethylamino) methyl-4- (p-fluorobenzyloxy) -1- (m-methoxyphenyl) -cyclohexanol, (1R, 2R) -3- (2-Dimethylaminomethylcyclohexyl) phenol, (1S, 2S) -3 (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol, (2R, 3R) -1-dimethylamino-3 (3-methoxy-phenyl ) -2-methyl-pentan-3-ol, (1RS, 3RS, 6RS) -6-dimethylaminomethyl-1- (3-methoxyphenyl) -cyclohexane-1,3-diol, 3- (2-dimethylaminomethyl-1 -hydroxycyclohexyl) phenyl 2- (4-isobutylphenyl) propionate, 3- (2-dimethylaminomethyl-1-hydroxycyclohexyl) phenyl 2- (6-methoxynaphthalene-2-yl) propionate, 3- ( 2-dimethylaminomethylcyclohex-1-enyl) -phenyl 2- (4-isobutyl-phenyl) -propionate, 3- (2-dimethylaminomethyl-cyclohex-1-enyl) -phenyl 2- (6-methoxynaphthalene-2-yl) yl) propionate, (RR-SS) -2-acetoxy-4-trifluoromethyl-benzoic acid 3- (2-dimethylaminom ethyl-1-hydroxycyclohexyl) phenyl ester, (RR-SS) -2-hydroxy-4-trifluoromethylbenzoic acid 3- (2-dimethylaminomethyl-1-hydroxy-cyclohexyl) -phenyl ester, (RR-SS) -4- Chloro-2-hydroxybenzoic acid 3- (2-dimethylaminomethyl-1-hydroxycyclohexyl) phenyl ester, (RR-SS) -2-hydroxy-4-methylbenzoic acid 3- (2-dimethylaminomethyl-1-hydroxycyclohexyl) -phenyl ester, (RR-SS) -2-hydroxy-4-methoxybenzoic acid 3- (2-dimethylaminomethyl-1-hydroxycyclohexyl) phenyl ester, (RR-SS) -2-hydroxy-5-nitrobenzoic acid 3- (2-dimethylaminomethyl-1-hydroxy-cyclohexyl) -phenyl ester, (RR-SS) -2 ', 4'-difluoro-3-hydroxy-biphenyl-4-carboxylic acid 3- (2-dimethylaminomethyl-1-hydroxy cyclohexyl) phenyl esters and their corresponding stereoisomeric compounds, in each case their corresponding derivatives, in particular amides, esters or ethers, and in each case their physiologically tolerated compounds, in particular their salts and solvates, particularly preferably their hydrochlorides.

The Compounds (1R *, 2R *) - 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol, (1R, 2R, 4S) -2- [dimethylamino) methyl-4- (p-fluorobenzyloxy) -1- (m-methoxyphenyl) -cyclohexanol or their stereoisomeric compounds or their physiologically compatible compounds, in particular their hydrochlorides, their derivatives, such as esters, ethers or amides and processes for their preparation are, for example from EP-A-693 475 or EP-A-780 369. The corresponding descriptions are hereby incorporated by reference and are considered part of the Epiphany.

The Active substances, if appropriate in the form of their ether, ester or acid derivatives, can each as pure stereoisomer, in particular enantiomer or Diastereomer, racemate or in the form of a mixture of stereoisomers, in particular the enantiomers and / or diastereomers, in one any mixing ratio, or in each case in the form of corresponding physiologically compatible Salts, or in each case in the form of corresponding solvates.

When suitable physiologically acceptable Salts are exemplified by the implementation of the free Bases of the respective active ingredient with an inorganic or organic Acid, preferably with hydrochloric acid, hydrobromic, Sulfuric acid, Phosphoric acid, methane, Benzenesulfonic, p-toluenesulfonic, carbonic, formic, acetic, propionic, oxalic, succinic, tartaric, mandelic, fumaric, maleic, lactic, malic, sebacic, citric, ascorbic, nicotinic, glutamic or aspartic acid obtained salts.

Other physiologically acceptable salts which may be mentioned by way of example are the salts obtained by reacting the free acids of the particular active substance with a suitable base. Examples which may be mentioned are the alkali metal salts, alkaline earth metal salts or ammonium salts [NH _x R _4-x ] ⁺ , where x = 0, 1, 2, 3 or 4 and R is a linear or branched C _1-4 alkyl radical.

Especially Preferably, the opioid buprenorphine (ATC code N02AE01) is free Base or in the form of one of its pharmaceutically acceptable Salts, preferably buprenorphine hydrochloride, buprenorphine saccharinate, Buprenorphine formate, buprenorphine mesylate, buprenorphine hydrogen citrate, Buprenorphine nicotinate or buprenorphine sebacinate.

It was surprising found that contained in the pressure-sensitive adhesive according to the invention multicyclic hydrocarbon with the above, physiologically active substances, without their stability and release behavior significantly negative to influence.

The TTS according to the invention preferably has a total area (contact area to the skin when used as intended) of 0.5 to 200 cm ² , more preferably 20 to 150 cm ² .

at the TTS according to the invention adjoins the sticky one Layer preferably directly to a carrier layer.

The backing preferably comprises a flexible, stretchable, breathable, durable material and may be colored, for example, skin colored. The carrier layer preferably has such a thickness that the TTS has sufficient mechanical stability. The carrier layer is preferably impermeable to active substance, ie it is impermeable to the active ingredient, at least in the region in which the carrier layer adjoins an active substance-containing matrix or a drug reservoir. If the carrier layer as such is not active substance-impermeable, an active substance-impermeable barrier layer should be arranged between the active substance-containing layer, ie the matrix or the active substance reservoir, and the carrier layer. This barrier layer is then preferably the same or different based on one or more materials, as follows for the carrier layer:
As examples of suitable materials of the carrier layer may be mentioned in particular polyester or copolyester, preferably polyethylene terephthalate; Polyolefins or olefin copolymers, preferably polyethylenes, polypropylenes or polybutylenes; polycarbonates; Polyethylene oxides; polyurethanes; polystyrenes; Polyamides or copolyamides; polyimides; polyvinyl acetates; polyvinyl chlorides; polyvinylidene; Copolymers, preferably acrylonitrile-butadiene-styrene terpolymers or ethylene-vinyl acetate copolymers, paper, textiles and mixtures thereof. Particularly preferably, the backing layer is based on a polyester, in particular polyethylene terephthalate, for example Hostaphan ^® RN. The carrier layer can also be metallized and / or pigmented or as a layer sequence of the abovementioned materials and a metal foil, particularly preferably a foil made of aluminum.

In a preferred embodiment is the carrier layer with an inorganic-organic Hybrid polymer coated. Inorganic-organic hybrid polymers, so-called ormocers are known in the art (see e.g. EP-A 0 358 011; EP-A 0 373 451; EP-A 0 610 831; EP-B 0 644 908; EP-A 0 792846; EP-A 0 934 989).

In a preferred embodiment has the carrier layer of the TTS according to the invention a layer thickness in the range of 5.0 to 125 microns, more preferably 10 to 115 microns more preferably 25 to 100 μm, most preferably 35 to 95 μm and in particular 50 to 85 microns on.

Prefers forms the carrier layer one of the two surface layers the system according to the invention, i.e. starting from the preferably directly to the carrier layer adjacent adhesive layer contains the TTS invention beyond the carrier layer prefers no further layer.

In a particularly preferred embodiment if the TTS according to the invention is made a carrier layer, a sticky one Layer and optionally a peelable protective layer.

The protective film preferably covers at least the drug-releasing region, preferably the entire adhesive layer. Before the application of TTS on the skin, the protective film is easily removable. The protective film is preferably silanized and / or fluoridated on at least the surface facing the adhesive layer and is removed prior to application of the system. This exposes the surface of the adhesive layer. The protective layer preferably directly adjoins the adhesive layer. The protective film may consist of polyethylene, polyester, polyethylene terephthalate, polypropylene, polysiloxane, polyvinyl chloride or polyurethane and optionally of treated paper fibers such as cellophane, optionally having a silicone, fluorosilicone or fluorocarbon coating. Preferably, the protective layer is based on a polyester, for example, Hostaphan ^® RNT. Preferably, the protective layer has a thickness of 10 to 100 μm, more preferably 25 to 50 μm.

In a further preferred embodiment of the TTS according to the invention it comprises several isolable subunits, which in turn in the form of an independent one Unit can be used as Transdermal Therapeutic Systems can, wherein the individual subunits with each other via preferably drug-free Border areas in which separation possibilities are provided, to a coherent one Unit are connected. Preferably lie linear perforations to separate the individual subunits from the related ones Unity before. Further preferred are cutting marks on the backing and / or the protective film, which the separation possibility of isolzelbaren Specify subunits of the unit. The separation possibilities are each preferably arranged so that they have a separation each related Subunit completely allow the unit according to the invention. The individual subunits can be the same or different. Are the subunits different, so can For example, they include the transdermally administered therein Substance in different dosages or with different release rates contain.

The preparation of the TTS according to the invention can be carried out by known production methods and conventional process steps, such as lamination, coextrusion, stamping, delamination, unwinding, cutting, rewinding, mounting or dosing (Verpackungs-Rundschau 4/2002, 83-84).

In another preferred embodiment the self-adhesive device is a drug-containing Plaster, wherein the active substance essentially only has its effect developed topically. The above in connection with the inventive TTS described, preferred embodiments apply to the active ingredient-containing according to the invention Plaster analog, with the only difference that the active ingredient Patch is made up in such a way that the active ingredient only topically, but not transdermally / systemically applied.

The The following examples serve to illustrate the invention are but not restrictive to be interpreted in terms of their scope:

Example 1:

160 g of DURO-TAK 387-2287 with a 51% solids content and 40 g of TCD alcohol DM {3 (4), 8 (9) -bis (hydroxymethyl) -tricyclo [5.2.1.0 ^2,6 ] -decane) } were mixed in a 500 ml round bottom flask and stirred for 30 minutes at 40 ° C, then for 30 minutes at room temperature, until a homogeneous mixture appeared (weight fraction TCD-alcohol DM 20 wt .-%). With the help of an Erichsen film applicator "Coatmaster 509 / MC-1" an adhesive layer of 120 μm thickness was applied to a hostaphan film RN 75 as carrier layer at a speed of 5 mm / s. The coated film was dried for 2.5 hours at room temperature and covered with a RNT 36 Hostaphan film as a protective film (S).

Example 2:

According to example 1, a patch was made, but DURO-TAK 387-2287 in an amount of 190 g and the TCD-alcohol DM in an amount of 10 g was used (weight fraction TCD-alcohol DM 5.0 wt .-%).

Example 3:

According to example 1 and 2, a patch was made using DURO-TAK 387-2287 but in an amount of 198 g and the TCD-alcohol DM in one Amount of 2 g was used (weight fraction TCD-alcohol DM 1.0 Wt .-%).

Example 4:

• a) Bestimmung der Klebkraft mit einer Zwick-Prüfmaschine auf einer Edelstahloberfläche Verwendetes Gerät: Materialprüfmaschine TestControl, Typ BTC FR2.5TH.D09, Fa. Zwick/Roell Ein 4 cm breites Stück Pflaster wurde längs zu ca. 75 % auf die obere Edelstahlplatte eines fahrbaren Schlittens aufgebracht. Der Schlitten wurde unterhalb des Messwertaufnehmers positioniert und befestigt. Das nicht verklebte Reststück wurde so in die Pneumatikbacken des Messgerätes eingespannt, dass das Pflaster senkrecht nach oben zeigte. Danach wurde das Pflaster bei Raumtemperatur mit einer Geschwindigkeit von 50 mm/min nach oben vom Schlitten abgezogen. Beim Abziehen wurde der Schlitten automatisch nachgeführt, damit das Pflaster stets senkrecht abgezogen wurde. Die Kräfte wurden in Abhängigkeit zum Weg aufgezeichnet.
• b) Zusätzlich wurde von 5 Testpersonen das gefühlte Klebkraftempfinden auf der menschlichen Haut bestimmt.

The bond strength of the patches obtained according to Examples 1 to 3 was measured in two different ways. For comparison, a plaster was prepared analogously to Examples 1 to 3, which, however, did not contain TCD-alcohol DM.

• a) Determination of bond strength with a Zwick testing machine on a stainless steel surface Equipment used: Material testing machine TestControl, type BTC FR2.5TH.D09, Zwick / Roell A 4 cm wide piece of plaster was longitudinally about 75% on the upper stainless steel plate applied mobile carriage. The carriage was positioned underneath the transducer and fastened. The non-glued remaining piece was clamped in the pneumatic jaws of the measuring device so that the plaster showed vertically upwards. Thereafter, the patch was peeled off the carriage at room temperature at a rate of 50 mm / min. When pulling off, the carriage was automatically tracked so that the pavement was always pulled vertically. The forces were recorded depending on the way.
• b) In addition, 5 test persons determined the perceived adhesion on the human skin.

The results of both adhesion measurements are summarized in the following table:

at the felt Adhesion means the value 4 the strongest and the value 1 the weakest adhesion.

As the measurements show, the pressure sensitive invention are characterized Adhesives characterized in that they adhere better to the skin than a comparative adhesive which does not contain a multicyclic hydrocarbon contains otherwise, however, has the same composition. In the 90 ° peel test with a stainless steel surface as a substrate, however, comes the increased adhesion under the selected Conditions are not expressed.

Claims (16)

A pressure sensitive adhesive containing at least one multicyclic, saturated or unsaturated hydrocarbon substituted with at least one functional group selected from the group consisting of - (CH ₂ ) _p OH, - (CH ₂ ) _p OC _1-6 alkyl, - (CH ₂ ) _p OCO-C _1-6 alkyl, - (CH ₂ ) _p SH, - (CH ₂ ) _p CN, - (CH ₂ ) _p N ₃ , - (CH ₂ ) _p NH ₂ , - (CH ₂ ) _p NHC _1-6 -alkyl, - (CH ₂ ) _p N (C _1-6 -alkyl) ₂ , - (CH ₂ ) _p NHCO-C _1-6 -alkyl, - (CH ₂ ) _p CHO, - (CH ₂ ) _p COC _1-6 -alkyl, - (CH ₂ ) _p CO ₂ H, - (CH ₂ ) _p CO ₂ C _1-6 -alkyl - (CH ₂ ) _p- CONHC _1-6- alkyl and - (CH ₂ ) _p CON (C _1-6 -alkyl) ₂ , where each p can be identical or different 0, 1, 2, 3, 4, 5 or 6. Adhesive according to claim 1, characterized in that that - p = 0 or 1 and / or - of the Hydrocarbon is tricyclic, and / or - the hydrocarbon Comprises 8 to 30 carbon atoms, and / or - the hydrocarbon is not aromatic. Adhesive according to claim 1 or 2, characterized in that the structure of the hydrocarbon of a tricyclo [ab1.0 ^{2, (a + 1)} ] hydrocarbon or a tricyclo [ab2.0 ^{2, (a + 1)} ] Hydrocarbon is derived, where a is 5, 6, 7 or 8 and b is 2, 3 or 4, respectively. Adhesive according to one of the preceding claims, characterized in that the hydrocarbon is a compound of general formula (I)

wherein n is 1, 2 or 3; R ₁ and R _{2 are} identically or differently selected from the group consisting of -CH ₂ OH, -CH ₂ NH ₂ and -CHO; and R ³ and R ^{4 are} each H or together form a C _1-4 alkylene bridge, where the C _1-4 -alkylene bridge is optionally substituted by one or two identical or different C _1-6 - Alkyl radicals may be substituted. Adhesive according to one of the preceding claims, characterized in that the structure of the hydrocarbon is derived from tricyclo [5.2.1.0 ^2,6 ] decane. Adhesive according to claim 5, characterized in that the hydrocarbon is selected from A group consisting of 3 (4), 8 (9) -bis (hydroxymethyl) tricyclo [5.2.1.0 ^2,6 ] decane, 3 (4), 8 (9) bis (aminomethyl) tricyclo [ 5.2.1.0 ^2,6 ] decane and 3 (4), 8 (9) -bis-formyltricyclo [5.2.1.0 ^2,6 ] decane. Adhesive according to one of the preceding claims, characterized characterized in that the weight fraction of the multicyclic hydrocarbon in the range of 0.1 to 50 wt .-%, based on the total weight of the adhesive. Adhesive according to one of the preceding claims, characterized characterized in that it contains at least one polymer selected from the group consisting of polyacrylates, acrylate copolymers, Ethylene-vinyl acetate copolymers, polyvinyl ethers, polyvinyl alcohols, Polyisobutylenes, polyurethanes, styrene-isoprene copolymers, styrene-butadiene copolymers, Silicones, rubbers, resins and optionally hydrogenated esters of rosin. Adhesive according to one of the preceding claims, characterized characterized in that it contains at least one excipient selected from the group consisting of skin permeation promoting substances, solvents, Solubilizers, Emulsifiers, crosslinkers, stabilizers, preservatives, Dyes, skin smoothing Means, perfumes, for reducing or preventing skin irritation transferable to the skin surface Compounds, thickeners and plasticizers. Self-adhesive device for attachment to the Skin comprising a sticky Layer containing a pressure sensitive adhesive according to one of claims 1 to 9 contains. Device according to claim 10, characterized in that that it is a Transdermal Therapeutic System or a plaster is. Transdermal therapeutic system according to claim 11, characterized in that it is a transdermally administered, contains physiologically active substance. Transdermal therapeutic system according to claim 12, characterized in that the physiologically active substance an active substance is selected from the group consisting of antiallergic drugs; antiarthritic; antiasthmatics; antibiotics; antidepressants; antidiabetics; antiepileptic drugs; antihistamines; antihypertensives; Anti-convulsive agents; Anti-migraine agents; antipyretics; anti-inflammatory drugs; antiviral agents; anxiolytics; cardiaca; cardiovascular Links; coronary dilators; corticosteroids; anti-inflammatory resources; enzymes; fungicides; Immunomodulators; vaccines; contraceptives; local anesthetics; Means for the treatment of alcohol and / or drug and / or drug dependence; Agents for the treatment of diseases of the central nervous system; Agents for the treatment of neurodegenerative diseases; narcotics and analgesics; nicotine; psychotropic drugs; sedatives; (Sexual) hormones; stimulants; tranquilizers; and vitamins. Transdermal therapeutic system according to claim 12 or 13, characterized in that the physiologically effective Substance is at least partially embedded in the adhesive layer. Transdermal Therapeutic System after one the claims 12 to 14, characterized in that the physiologically active Substance is embedded in a matrix or in a reservoir is present. Use of a multicyclic, saturated or unsaturated Hydrocarbon as defined in any one of claims 1 to 6, as a tackifier in a pressure-sensitive adhesive.